Twist1-Overexpression Induces Glycolytic Reprogramming and Atp Production In 293t Cells

Reprogramming of glucose metabolism in cancer cells triggers tumor development. Most cancer cells provide the energy needed from aerobic glycolysis called the "Warburg effect" to promote uncontrolled proliferation and invasion. Ther efore, direct regulator molecules of aerobic glycolysis remain active research targets. Epithelial mesenchymal transition (EMT) is the main mechanism that promotes cancer invasion and poor prognosis. One of the key effector molecules of the EMT is TWIST1. In this study, we sought to investigate the role that TWIST1 has in driving glycolytic programming and cellular energy charges in 293T cells by overexpressing TWIST1 in 293T cells. Plasmid vectors were successfully transfected by lipofectamine 2000 and mRNA expressions of interested genes were assessed. Glucose, lactate and pH levels of culture supernatants were determined by radiometer analyzer. The cellular energy charge of the cells were calculated from ATP, ADP and AMP data analyzed by HPLC. Here, we found that TWIST1 transcription factor, which has highly conserved sequences, is an important regulator for aerobic glycolysis. We found that TWIST1 increases the expression of glycolytic genes such as HK2, PKM2, LDH , PFKM and G6PD, the production of lactate and extracellular acidification in 293T cells. We have also determined that TWIST1 promotes aerobic glycolysis metabolism by providing cellular energy exchange. TWIST1 overexpression reduced AMP/ATP and ADP/ATP ratios in 293T cells, with further increase seen in ATP production. By this work, we confirmed that TWIST1 is closely related to the glycolysis pathway and is an important regulator of the Warburg effect.

PDF

___

1. Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci 2016; 41: 211-218.

2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 4; 144: 646-74.

3. Guo X, Li H, Xu H, Woo S, Dong H, Lu F, et. al. Glycolysis in the control of blood glucose homeostasis. Acta Pharmaceutica Sinica B 2012; 2: 358-367.

4. Israelsen WJ, Vander Heiden MG. Pyruvate kinase: Function, regulation and role in cancer. Semin Cell Dev Biol 2015; 43: 43-51.

5. Galluzzi L, Kepp O, Tajeddine N, Kroemer G. Disruption of the hexokinase-VDAC complex for tumor therapy. Oncogene 2008; 27: 4633-4635.

6. Pastorino JG, Hoek JB. Regulation of hexokinase binding to VDAC. J Bioenerg Biomembr 2008; 40: 171-182.

7. Valvona CJ, Fillmore HL, Nunn PB, Pilkington GJ. The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor. Brain Pathol 2016; 26: 3-17.

8. Yang HC, Wu YH, Yen WC, et al. The Redox Role of G6PD in Cell Growth, Cell Death, and Cancer. Cells 2019; 8(9).

9. Howard TD, Paznekas WA, Green ED, et al. Mutations in TWIST, a basic helix-loop-helix transcription factor, in Saethre-Chotzen syndrome. Nat Genet 1997; 15: 36-41.

10. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-939.

11. Cimen B, Turkozkan N, Seven I, Unlu A, Karasu C. Impaired Na+,K+-ATPase activity as a mechanism of reactive nitrogen speciesinduced cytotoxicity in guinea pig liver exposed to lipopolysaccharides. Mol Cell Biochem 2004; 259: 53-57.

12. Cairns RA, Harris I, McCracken S, Mak TW. Cancer cell metabolism. Cold Spring Harb Symp Quant Biol 2011; 76: 299-311.

13. Gort EH, van Haaften G, Verlaan I, et al. The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2alpha. Oncogene 2008; 27: 1501-1510.

14. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010; 330: 1340-1344. 15. Brizel DM, Schroeder T, Scher RL, et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in headand-neck cancer. Int J Radiat Oncol Biol Phys 2001; 51: 349-353.

16. San-Millan I, Brooks GA. Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect. Carcinogenesis 2017; 38: 119-133.

17. Justus CR, Dong L, Yang LV. Acidic tumor microenvironment and pH-sensing G proteincoupled receptors. Front Physiol 2013;4: 354.

18. Kim SY. Cancer Energy Metabolism: Shutting Power off Cancer Factory. Biomol Ther (Seoul) 2018; 26: 39-44.

19. Zhang Y, Yang JM. Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention. Cancer Biol Ther 2013; 14: 81-89.

20. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 2005; 280: 32081-32089.

21. Jin Q, Feng L, Behrens C, et al. Implication of AMP-activated protein kinase and Aktregulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res 2007; 67: 11630-11639.

22. Garcia D, Shaw RJ. AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance. Mol Cell 2017; 66: 789- 800.

23. Fay JR, Steele V, Crowell JA. Energy homeostasis and cancer prevention: the AMPactivated protein kinase. Cancer Prev Res (Phila) 2009; 2: 301-309.

24. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.

25. Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest 2013; 123: 3685-3692.

26. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 2013; 123: 3664-3671.

27. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009; 15: 6479- 6483.

28. Dhanasekaran R, Baylot V, Kim M, et al. MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. Elife 2020; 14: 9. pii: e50731.

29. Selmi A, de Saint-Jean M, Jallas AC, et al. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma. Cancer Lett 2015; 357: 412-418.

30. Zhao Z, Rahman MA, Chen ZG, Shin DM. Multiple biological functions of Twist1 in various cancers. Oncotarget 2017; 21: 20380- 20393.

31. Anderson M, Marayati R, Moffitt R, Yeh J. Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer. Oncotarget 2016; 8: 56081- 56094.

32. Ahsan H, Halpern J, Kibriya MG, et al. A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. Cancer Epidemiol Biomarkers Prev 2014; 23: 658-669.

33. Zhang Z, Deng X, Liu Y, Liu Y, Sun L, Chen F. PKM2, function and expression and regulation. Cell Biosci 2019; 26: 9:52.

34. Miao P, Sheng S, Sun X, Liu J, Huang G. Lactate dehydrogenase A in cancer: a promising target for diagnosis and therapy. IUBMB Life 2013; 65: 904-910.

35. Miyajima H, Takahashi Y, Kaneko E. Characterization of the glycolysis in lactate dehydrogenase-A deficiency. Muscle Nerve 1995; 18: 874-878.

36. Miyajima H, Takahashi Y, Suzuki M, Shimizu T, Kaneko E. Molecular characterization of gene expression in human lactate dehydrogenase-A deficiency. Neurology 1993; 43: 1414-1419.

37. Koukourakis MI, Giatromanolaki A. Warburg effect, lactate dehydrogenase, and radio/chemo-therapy efficacy. Int J Radiat Biol 2019; 95: 408-426.

38. Yang HC, Wu YH, Yen WC, et al. The Redox Role of G6PD in Cell Growth, Cell Death, and Cancer. Cells 2019; 8: E1055.

39. Chen J, Ye C, Dong J, et al. Metabolic classification of circulating tumor cells as a biomarker for metastasis and prognosis in breast cancer. J Transl Med 2020; 18: 59.

40. Spencer NY, Stanton RC. Glucose 6- phosphate dehydrogenase and the kidney. Curr Opin Nephrol Hypertens 2017; 26: 43- 49.

41. Wang J, Yuan W, Chen Z, Wu S, Chen J, Ge J, Hou F, Chen Z. Overexpression of G6PD is associated with poor clinical outcome in gastric cancer. Tumour Biol 2012; 33: 95-101.

42. Lu M, Lu L, Dong Q, et al. Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition. Acta Biochim Biophys Sin (Shanghai) 2018; 50: 370-380.

43. Zhang C, Zhang Z, Zhu Y, Qin S. Glucose-6- phosphate dehydrogenase: a biomarker and potential therapeutic target for cancer. Anticancer Agents Med Chem 2014; 14: 280- 289.

44. Stubbs M, McSheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today 2000; 6: 15-19.

45. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM. MRI of the tumor microenvironment. J Magn Reson Imaging 2002; 16: 430-450.

46. Sridaran D, Ramamoorthi G, Mahaboob Khan R, Kumpati P. Oxystressed tumor microenvironment potentiates epithelial to mesenchymal transition and alters cellular bioenergetics towards cancer progression. Tumour Biol 2016; 37: 13307-13322.

47. Abbaszadeh Z, Çeşmeli S, Biray Avcı Ç. Crucial players in glycolysis: Cancer progress. Gene 2020; 726: 144158.